FGF23 is a key factor in the pathogenesis of chronic kidney disease–metabolic bone disease, where significant increases in plasma FGF23 concentrations occur in humans, cats and dogs in parallel with the stages of kidney disease [9,10,11]. Here, FGF23 is linked to chronic kidney disease.